rsz_3logo_saliva-direct-rgb
Liberty16 and SalivaDirect

Easier and more accessible testing for SARS-CoV-2 (COVID-19)

Ubiquitome has partnered with the Yale School of Public Health to enhance public access to COVID-19 testing, with United States Food and Drug Administration (FDA) emergency use authorization (EUA) of the combination of SalivaDirect™ with Ubiquitome’s Liberty16 mobile real time-PCR.

In Yale testing the Liberty16 displayed performance similar to large, lab-bound instruments.

Proteinase K Primer/Probe RT-qPCR kit RT-qPCR instrument LOD Positive replicates Mean Ct value (SD)
Thermo IDT NEB Luna (2x) Agilent AriaMX 6 copies/μL 100% (20/20) 30.3 (0.4)
Thermo Eurofins NEB Luna (2x) Liberty16 12 copies/μL 100% (20/20) 35.18 (0.7)
Thermo IDT NEB Luna (2x) CFX384 Touch 6 copies/μL 100% (20/20) 36.25 (0.4)

Recent news

New Zealand’s Ubiquitome signs NIH RADx contract
New Zealand’s Ubiquitome signs NIH RADx contract
7 October, 2020

Its Liberty16 open system RT-PCR offers rapid, mobile testing for COVID Auckland, New Zealand, October 7, 2020: New Zeal...

​Ubiquitome’s Liberty16 Attracts Swiss Giant
​Ubiquitome’s Liberty16 Attracts Swiss Giant
19 May, 2020

Ubiquitome has signed an exclusive agreement for Swiss headquartered DKSH to market and sell its mobile, battery powered...

Lib16 with app@1920x
The Liberty 16

When small becomes big

Stay ahead of the curve with the mobile, real-time system PCR that fits in the palm of your hand.

An app is also available for your iPhone

Download_on_the_App_Store_Badge_US-UK_RGB_blk_092917

Smaller

Battery-powered

Cloud-enabled

Speed to result

"Costly instruments for real-time PCR analysis often stand in the way of equitable access for under resourced communities and countries and sustainability of testing systems"

Dr Anne Wyllie, Yale School of Public Health (on why they partnered with Ubiquitome)

Ubiquitome’s world class team is changing how the world accesses and shares genomic information.

About us